Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Glucagon-like peptide drugs and heart risk in people with sleep apnea and obesity in real life

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Obstructive sleep apnea (OSA) is a well-established risk factor for cardiovascular disease.

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce cardiovascular risk.
  • GLP-1RAs could improve the severity of obstructive sleep apnea.
  • There is a significant knowledge gap regarding the effects of GLP-1RAs on cardiovascular events in patients with OSA.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declarations. Consent for publication: Not applicable. Ethics approval and consent to participate: This study used de-identified, aggregate-level data from the TriNetX research network. No individual patient-level data were accessed. The study did not require institutional review board approval or informed consent in accordance with the policy of the Institutional Review Board of National Cheng Kung University Hospital. Competing interests: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief